Ranbaxy Malaysia has been allocated the site for setting up its greenfield manufacturing facility in Malaysia. The company signed a ‘letter of offer’ agreement with Kulim Hi Tech Park (KHTP), a wholly-owned state agency and industrial park that houses various other leading industries. KHTP is located at Kulim in the state of Kedah, Malaysia.
The agreement was signed by T Jeyabalan Thangarajah, Managing Director, RMSB and Tuan Haji Muhammad Sobri, President, KHTP in the presence of representatives of the Ministry of Investment Development Authority (MIDA) and Arun Sawhney, Chief Executive Officer and Managing Director, Ranbaxy.
The Ranbaxy greenfield facility will be built on an area of around 15 acres with an investment of around $35 million providing employment to over 200 people. This will be Ranbaxy’s second manufacturing plant in Malaysia. Last year in September, the Government of Malaysia gave an approval to RMSB for setting up a greenfield manufacturing facility in Malaysia as an Entry Point Project (EPP).
Commenting on the signing ceremony, Thangarajah said, “Ranbaxy established its foothold in Malaysia three decades back and since then has been offering high quality, affordable generic medicines to the Malaysian healthcare system. The new greenfield facility reinforces our long term commitment.” He further added, “In addition to serving the local market, the new facility will also export products to the ASEAN markets, Middle East, Europe, Sri Lanka, China and other select nations.”
The RMSB new facility would manufacture dosage forms including tablets and capsules primarily in the cardiovascular, anti diabetic, anti-infective and gastrointestinal segments. Ranbaxy’s total output in Malaysia will be increased from one billion doses/annum to three billion doses/annum when the new facility is fully operational.
EP News Bureau – Mumbai
